SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending after delivering a strong earnings beat and significantly raised FY27 guidance, with robust cloud and AI infrastructure growth, leading the community to hail it as a validation of AI spending and a powerful rebuttal to prior capital expenditure concerns plaguing the software sector.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

TSSI is trending ahead of its highly anticipated Q4 earnings, with community sentiment driven by an earlier-than-expected release date and strong tailwinds from key partner Dell's surging AI server backlog. Investors are closely watching for a potential beat and positive guidance, fueled by the company's low float, high short interest, and its critical role in the ongoing AI data center infrastructure buildout.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending as its acquisition of Diligent Robotics signals an expansion into healthcare, while NVIDIA's public endorsement highlights its "Physical AI" in urban delivery. The community is actively debating the company's growth potential and short-squeeze prospects, balancing optimism from new markets and partnerships against valuation and profitability concerns.

The Campbell's Co. engages in the business of manufacturing and marketing food and beverage products. It operates under the Meals and Beverages, and Snacks segments. The Meals and Beverages segment includes soup, meals, and beverage products in retail and foodservice. The Snacks segment offers cookies, crackers, bakery, and frozen products. The company was founded by Joseph Campbell and Abraham Anderson in 1869 and is headquartered in Camden, NJ.

Campbells Co (The)

Campbell Soup Co.

Campbell Soup Co. is heavily discussed following a disappointing earnings report and reduced full-year guidance, which has intensified concerns over debt and weak consumer demand. While many express strong bearish sentiment and speculate on further declines to multi-decade lows, others highlight the stock's current valuation as "insanely cheap" for its dividend and strong performing brands like Rao's, anticipating a potential rebound.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending following a post-earnings sell-off driven by a revenue miss and the U.S. Space Force's termination of a significant SCAR contract, despite the company's intent to recompete. The community is debating if the sharp decline is an overreaction, pointing to strong underlying drone demand from global conflicts and robust backlog as reasons for a potential rebound.

OppFi, Inc. is a tech-enabled, mission-driven specialty finance platform, which engages in the provision of community banks to extend credit access to everyday Americans. It supports consumers, who are turned away by mainstream options, to build better financial health, through transparency, responsible lending, financial inclusion, and an excellent customer experience. The company was founded by Todd G. Schwartz and Theodore Schwartz in 2012 and is headquartered in Chicago, IL.

OppFi Inc - Ordinary Shares - Class A

OppFi Inc

OppFi is trending following robust earnings and upbeat 2026 guidance, highlighting record profitability driven by AI-powered underwriting, yet the community debates whether the stock's low valuation and high short interest will lead to a significant re-rating.

Sprinklr, Inc. engages in the provision of enterprise cloud software products. It enables organizations to do marketing, advertising, research, care, sales, and engagement across modern channels including social, messaging, chat, and text through its unified customer experience management software platform. The company was founded by Ragy Thomas on September 24, 2009 and is headquartered in New York, NY.

Sprinklr Inc - Ordinary Shares Class A

Sprinklr Inc

Sprinklr (CXM) is actively discussed after beating Q4 earnings and authorizing a $200 million share repurchase program, with many in the community highlighting its strong profitability and cash position, even as some express caution regarding its forward revenue guidance.

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut in 2003 and is headquartered in Jerusalem, Israel.

Brainsway Ltd - ADR

Brainsway Ltd.

BrainsWay is trending following strong financial results and multiple FDA clearances for its Deep TMS system, including an accelerated depression treatment protocol and expanded indication for adolescents. The community is actively discussing how Optum's broadened coverage significantly enhances market access and adoption for these innovative neurostimulation therapies.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is trending due to significant developments like its 'Mission 70' proposal, aimed at drastically reducing token inflation, and expanding real-world adoption through national subnets in Switzerland and a new partnership with the Pakistan Digital Authority. These advancements are fueling community debate over whether ICP's foundational role in decentralized cloud and AI infrastructure will finally overcome historical price skepticism.

Cintas Corp. engages in the provision of corporate identity uniforms through rental and sales programs. It operates through the following segments: Uniform Rental and Facility Services, First Aid and Safety Services, and All Other. The Uniform Rental and Facility Services segment consists of the rental and servicing of uniforms and other garments including flame resistant clothing, mats, mops and shop towels, and other ancillary items. The First Aid and Safety Services segment includes first aid and safety products and services. The All Other segment contains fire protection services and its direct sale business. The company was founded by Richard T. Farmer in 1968 and is headquartered in Cincinnati, OH.

Cintas Corporation

Cintas Corporation is capturing investor attention following a strong earnings beat and raised full-year guidance that propelled shares to new all-time highs. Discussions are also circulating around the termination of its acquisition talks with UniFirst, with community members debating the valuation of this consistent business services leader.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 9,253.7%

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) saw a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 1,411,103 shares...

Best Biotech Stocks To Follow Today - March 7th

Danaher, Moderna, Vertex Pharmaceuticals, argenex, Iovance Biotherapeutics, Edesa Biotech, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Pardeep Nijhawan Purchases 10,000 Shares of Edesa Biotech (NASDAQ:EDSA) Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 10,000 shares of Edesa Biotech stock in a transaction dated Thursday, March 5th. The shares were purchased at an...

Edesa Biotech (NASDAQ:EDSA) CEO Pardeep Nijhawan Acquires 10,000 Shares

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 10,000 shares of the firm's stock in a transaction on Thursday, March 5th. The shares were acquired at an average...

Edesa Biotech (NASDAQ:EDSA) CEO Buys $36,300.00 in Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan acquired 10,000 shares of the business's stock in a transaction dated Tuesday, March 3rd. The stock was acquired at an average...

Pardeep Nijhawan Acquires 30,000 Shares of Edesa Biotech (NASDAQ:EDSA) Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 30,000 shares of the business's stock in a transaction on Friday, February 27th. The shares were purchased at an...

<ul class="summary-bullets"><li>The company on Tuesday reported results from a 278-patient population, including 104 patients requiring invasive mechanical ventilation (IMV) as well as 174 non-IMV patients.</li><li>Overall rates of adverse events, serious adverse events, infections and treatment discontinuations were low and similar between the paridiprubart and placebo groups, the company said.&nbsp;</li><li>The company is advancing regulatory discussions and evaluating strategic collaborations and partnership opportunities, the CEO said.</li></ul>Shares of Edesa Biotech, Inc. jumped 76% on Tuesday after the company announced that data from a late-stage study of its experimental drug for the treatment of Acute Respiratory Distress Syndrome affirmed statistically significant mortality reductions.Acute respiratory distress syndrome (ARDS) is a life-threatening, rapid-onset lung failure caused by severe inflammation, which fills the air sacs with fluid and restricts oxygen absorption.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/24/3243711/0/en/Edesa-Biotech-Reports-Additional-Positive-Results-from-Phase-3-Paridiprubart-Study.html">reported</a> results from a 278-patient population, including 104 patients requiring invasive mechanical ventilation (IMV) as well as 174 non-IMV patients.Edesa Biotech said that its experimental drug paridiprubart demonstrated statistically significant reduction in 28-day mortality in the full population to 24% from 33%.Further, treatment benefits were consistent across severity groups and in patients with serious comorbidities. Overall rates of adverse events, serious adverse events, infections, and treatment discontinuations were low and similar between the paridiprubart and placebo groups, the company said. &nbsp;<h2 class="st-heading-2">CEO Expresses Optimism</h2>“The consistency of mortality reduction and clinical improvement across all 278 randomized patients, including less severe patients as well as those with ARDS complicated by acute kidney injury, sepsis and pneumonia, underscores the versatility and transformative potential of paridiprubart to address multiple critical unmet medical needs,” said CEO Par Nijhawan.The chief also added that the company is advancing regulatory discussions and evaluating strategic collaborations and partnership opportunities which could potentially accelerate development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EDSA stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user said that they are now waiting for that “first real surge” in stock price.<stembedurl>https://www.stocktwits.com/topstockalerts/message/645761015</stembedurl><a href="https://stocktwits.com/symbol/EDSA">EDSA stock</a> has dropped 29% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ark-cathie-wood-rebuts-citrini-ai-thought-piece/cZRw3pOR4Cp">ARK’s Cathie Wood Rebuts Citrini AI Thought Piece, Predicts Opportunities After Near-Term Disruptions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did EDSA Stock Rally More Than 70% Today?

Edesa Biotech said that data from a late-stage study of its experimental drug for the treatment of Acute Respiratory Distress Syndrome affirmed statistically significant mortality reductions.

Equity

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

EDSA
Edesa Biotech Inc

Feed

News

Sentiment

Fundamentals

Info

Latest EDSA News

EDSAEdesa Biotech Inc